AllAnalyst Report
logoMorningstar•August 18, 2021

Alcon Inc.: Alcon Surprises With Better-Than-Expected Q2 Results Despite Delta-Variant Headwinds; Maintain FVE

Symbols
ALC
Sector(s)
Healthcare
Rating
Current Price
$78.77
Fair Value
Economic Moat
Stewardship
Summary

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Actions

Download Full Report

Related Reports

View more related reports

Analyst Profile

Aaron Degagne

Equity Analyst
Aaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.